A Food and Drug Administration advisory committee stopped short of supporting a clear-cut new limit on kidney-failure patients' use of the blockbuster anemia drugs made by Amgen Inc. and Johnson & Johnson, but members split over what doses of the medications are appropriate.Click here to access (sub. req.).
Wednesday, September 12, 2007
Latest FDA news on anemia drugs
From the Wall Street Journal article: